Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations

10 Apr 2020

Abstract excerpt

The development of thrombotic events is common among patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We studied the influence of pathogenic mutations frequently associated with myeloid malignancies on thrombotic events using next-generation sequencing (NGS) in an initial cohort of 68 patients with myeloproliferative neoplasms (MPN). As expected, the presence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32290079
DOI: 10.3390/cancers12040934

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 MutationsPMID 32290079Read ↗

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.Semantic proximity Read ↗

DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational studySemantic proximity Read ↗

[Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].Semantic proximity Read ↗

Clinical Impact of Next-Generation Sequencing-Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision OncologySemantic proximity Read ↗

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.Semantic proximity Read ↗

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential ThrombocytosisSemantic proximity Read ↗

Development and validation of a multiple factor-based prognostic score system of thrombosis in polycythemia vera (MFPS-PV)Semantic proximity Read ↗

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.